Unknown

Dataset Information

0

Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis.

ABSTRACT:

SUBMITTER: Palandri F 

PROVIDER: S-EPMC7791065 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature

Json Xml

Similar Datasets

Unknown Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation.
| S-EPMC5580275 | biostudies-literature
Unknown A Prognostic Model to Predict Ruxolitinib Discontinuation and Death in Patients with Myelofibrosis.
| S-EPMC10605705 | biostudies-literature
Unknown Increased Rate of Anemia and Discontinuation in Older Patients with Myelofibrosis Treated with Ruxolitinib.
| S-EPMC12524875 | biostudies-literature
Unknown Management of myelofibrosis after ruxolitinib failure.
| S-EPMC7237516 | biostudies-literature
Unknown Definition and management of ruxolitinib treatment failure in myelofibrosis.
| S-EPMC4315890 | biostudies-literature
Unknown Revised "iRR6" model in intermediate-1 risk myelofibrosis patients treated with ruxolitinib.
| S-EPMC12369922 | biostudies-literature
Unknown Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis.
| S-EPMC5668021 | biostudies-literature
Unknown Efficacy of ruxolitinib on hepatomegaly in patients with myelofibrosis.
| S-EPMC4895165 | biostudies-literature
Unknown Ruxolitinib for the management of myelofibrosis: Results of an international physician survey.
| S-EPMC8190959 | biostudies-literature
Unknown Ruxolitinib is effective in patients with intermediate-1 risk myelofibrosis: a summary of recent evidence.
| S-EPMC4975083 | biostudies-literature